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Diabetes accounted for at least $US465 billion worth 
of health expenditure in 2011, 11% of the total 
healthcare expenditure in the 20 - 79-year-old age 
range.[1] According to the International Diabetes 
Federation (IDF), there are 1.9 million adults with 
diabetes in this age range in South Africa.[1]
The benefits of lifestyle change, exercise and weight loss are 
definite but difficult to achieve and maintain. Oral medications such 
as insulin sensitisers and insulin secretagogues are first- and second-
line agents in the type 2 diabetes treatment armamentarium and are 
relatively inexpensive. Newer, more expensive agents (the DPP-IV 
inhibitors and GLP-1 analogues) have been added to the South 
African type 2 diabetes treatment algorithm and, although expensive, 
may further delay the introduction of insulin.[2]
Ultimately, however, progressive beta cell failure in patients with 
type 2 diabetes mellitus results in an ever-increasing proportion of 
patients requiring injected insulin to obtain and maintain glycaemic 
targets. Insulin remains the most effective glucose-lowering 
therapy.[2] The addition of insulin dramatically increases the cost 
of management, with greater requirements for trained diabetes 
personnel, blood glucose test strips, injection devices, monitoring 
and the insulin itself.
Biosimilar insulins have the potential to dramatically lower 
healthcare costs by delivering insulin with similar anti-glycaemic 
effect and adverse reaction profile to standard, more expensive 
insulin preparations.[3] The purpose of this study is to confirm 
equivalence in glycaemic outcomes and side-effect profiles between 
Biosulin 30/70 and other human premixed insulin preparations on 
the South African market in a clinical practice setting.
Methods
Seventy-seven subjects with type 1 (n=18) and type 2 diabetes 
mellitus (n=59) were enrolled in this interventional, observational, 
multicentre, open-label, prospective study.
Ethics approval was obtained from the Human Research Ethics 
Committee of the University of the Witwatersrand. Study subjects 
were recruited from the Hillbrow Community Hospital Diabetes 
Clinic (a state hospital facility) and two Centre for Diabetes and 
Endocrinology (CDE) centres in Johannesburg (private medical 
facilities). A real-world practice setting was used to gather data on 
the performance of the insulins across a range of economic and social 
strata in subjects with type 1 and type 2 diabetes.
Subjects who agreed to participate in the trial and after signing 
informed consent were enrolled and had anthropometrics measured. 
The Biosulin equivalence in standard therapy (BEST) 
study − a multicentre, open-label, non-randomised, 
interventional, observational study in subjects using 
Biosulin 30/70 for the treatment of insulin-dependent 
type 1 and type 2 diabetes mellitus
D Segal,1 MB BCh, FAAP, FACE; D Tupy,2 MD;  L Distiller,3 BSc, MB BCh, FCP (SA), FRCP (London), FACE
1 Department of Paediatrics, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa
2 Department of Internal Medicine, Hillbrow Community Hospital, Johannesburg, South Africa
3 Centre for Diabetes and Endocrinology, Johannesburg, South Africa
Corresponding author: D Segal (david@endo.co.za)
Introduction. The need for more cost-effective insulin therapy is critical in reducing the burden on patients and health systems. Biosimilar 
insulins have the potential to dramatically lower healthcare costs by delivering insulin with a similar anti-glycaemic effect and adverse 
reaction profile.
Objectives. The purpose of this study was to confirm equivalence in glycaemic outcomes and side-effect profiles between Biosulin 30/70 
and other human premixed insulin preparations on the South African market in a clinical practice setting.
Methods. Subjects in this interventional, observational, multicentre, open-label, prospective study were switched from their existing human 
premix insulin (Actraphane, Humulin 30/70 or Insuman) to the study insulin Biosulin 30/70. The primary endpoint was the change in 
HbA1c from baseline to 6 months.
Results. Seventy-seven adult patients with type 1(n=18) or type 2 (n=59) diabetes were enrolled. The baseline HbA1c in the overall cohort 
was 7.9%, 8.0% at 3 months (p=0.50) and 7.6% at 6 months (p=0.14).There was a small increase in the total daily dose of insulin used in 
both the type 1 and type 2 cohort, from 0.62 to 0.65 units/kg/day (p=0.0004). There was no significant difference in weight in the study 
subjects during the 6-month period on Biosulin 30/70 (p=0.67).
Conclusion. Biosulin 30/70 achieved at least equivalent glycaemic control to existing human premix insulins, with no reported new or 
severe adverse events. Increased use of biosimilar insulins has the potential for significant cost savings.
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The subjects were then switched from their existing human premix 
insulin (Actraphane, Humulin 30/70 or Insuman) to the study insulin 
Biosulin 30/70 after education and demonstration on the new delivery 
device (the biopen). Most subjects were familiar with pen injection 
devices. Insulin dosages were kept unchanged at the first visit, but 
adjusted by the managing physician at subsequent 3-month visit 
according to their usual practice. No titration algorithm was in force. 
All oral hypoglycaemic agents and adjuvant medications were continued 
unchanged.
Blood was drawn at baseline, 3 months and 6 months for measurement 
of HbA1c. All samples were tested at the National Health Laboratory 
Services (NHLS) by a turbidimetric inhibition immunoassay (Cobas 
Integra 400) with a detection limit of 0.1 g/dl. The intra- and inter-assay 
coefficients of variation were 0.8% and 1.1% respectively. The change in 
HbA1c from baseline to 6 months was considered the primary endpoint 
of the study. All adverse events, and in particular the incidence and 
severity of any hypoglycaemic events, were recorded.
Results
Seventy-seven adult patients with type 1 (n=18) or type 2 (n=59) 
diabetes were enrolled at the 3 study centres. Thirty-six (47%) of the 
77 subjects were male. The type 1 cohort had a mean duration of 
diabetes of 7.2 years (range 1 - 21 years) and the type 2 cohort had 
been requiring insulin for a mean of 7.4 years (range 1 - 21 years). 
Patient characteristics are in Table 1. Subjects were grouped according 
to type of diabetes for better separation of subject characteristics but 
were pooled for the HbA1c data.
The baseline HbA1c in the overall cohort was 7.9%, 8.0% at 
3  months (p=0.50) and 7.6% at 6 months (p=0.14).The type 1 
cohort baseline HbA1c was 8.4% and improved to 8.0% at 6 months 
(p=0.41). The type 2 cohort baseline HbA1c was 7.7%, improving to 
7.4% at 6 months (p=0.19).  There was no statistical difference in the 
primary endpoint of HbA1c after 6 months in the combined cohort 
or in the type 1 or type 2 cohorts on Biosulin 30/70 (p=0.14) (Fig. 1).
There was a small but significant increase in the total daily dose 
of insulin used in both the type 1 and type 2 cohorts, from 0.62 to 
0.65 u/kg/day (p=0.0004). There was no significant difference in 
weight in the study subjects during the 6-month period on Biosulin 
30/70. The mean weight at baseline for the type 1 cohort was 68.1 kg, 
increasing to 68.6 kg at study end (p=0.52), and 91.2 kg declining to 
90.8 kg (p=0.42) in the type 2 cohort. As expected, their BMIs were 
essentially unchanged (p=0.74).
There were no severe hypoglycaemic episodes reported by the 
subjects in the 1 month prior to the study (on their pre-study 
insulin) and for the duration of the study on Biosulin 30/70. Most of 
the subjects were managed at the state hospital facility and did not 
perform self-monitored home blood glucose measurements.
Discussion
With the humanitarian and economic burdens of diabetes increasing, 
and with the greatest demands and increases in developing countries, 
the need for more cost-effective insulin therapy is critical in reducing 
the financial burden on patients and health systems.
Biosimilars are distinctly different from generic drugs. Generic 
drugs are chemical entities that have an identical chemical composition 
to the parent drug and are relatively easy to manufacture. Typically, 
the delivered cost of a generic product is 10% to 70% that of the 
‘parent’ drug.
Biosimilars, on the other hand, are protein compounds that rely on 
post-translational modification and folding for efficacy, and therefore 
are bio-equivalent rather than bio-identical. Because they are foreign 
proteins, and can elicit an antibody response that can attenuate their 
function or cause unwanted side-effects, biosimilars must follow 
precise manufacturing, processing and purification procedures, and 
are regulated to pass stringent laboratory and clinical trials before 
approval. Such biopharmaceuticals are made by only a handful of 
manufacturers using similar techniques involved in producing the 
parent product, and are therefore termed biosimilar. With many 
of the insulins reaching the end of their patents, these medications 
become attractive targets for production of biosimilar insulins. One 
of the obstacles to the adoption of biosimilar insulin is the notion that 
Table 1. Patient characteristics and data comparison
Total Type 1 Type 2
N 77 18 59
Sex (male/female) 36/41 7/11 29/30
Age (years), mean (range) 49.7 (26 - 75) 38.9 (26 - 60) 52.1 (26 - 75)
Duration of insulin use 
(years), mean
7.3 7.2 7.4
Baseline 6 months p-value Baseline 6 months p-value Baseline 6 months p-value
TDD (u/kg/day) mean±SD 0.62±0.19 0.65±0.20 0.0004 0.71±0.19 0.76±0.18 0.02 0.59±0.19 0.61±0.17 0.01
Weight (kg), mean±SD 85.3±17.2 85.1±16.9 0.67 68.1±9.6 68.6±9.5 0.52 91.2±15.2 90.8±15.1 0.42
BMI (kg/m2), mean±SD 31.1±6.0 31.1±5.9 0.74 25.9±4.1 26.1±4.0 0.55 32.9±5.5 32.8±5.5 0.48
HbA1c (%), mean ± SD 7.9±1.6 7.6±1.7 0.14 8.4±1.6 8.0±1.8 0.41 7.7±1.5 7.4±1.7 0.19
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Fig. 1. HbA1c at baseline and after 6 months of therapy with Biosulin 30/70.
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it may be less effective. Some of the concerns have been legitimate, 
with a number of biosimilar insulins failing to meet stringent 
registration standards.[4] However, ongoing vigilance and extensive 
clinical trials will continue to be required to ensure the safety and 
efficacy of new biosimilar insulins.
Biosulin 30/70 L, N and R were approved for use in South Africa 
by the Medicines Control Council (MCC) in 2005. To achieve this, 
Biosulin trials by Pharmovs in South Africa demonstrated to the 
MCC that Biosulin has the same clinical properties as the parent 
insulin already on the market, and additionally that it did not have 
any unexpected and new adverse effects in diabetics.
In this non-randomised, interventional 6-month study comparing 
glycaemic control of existing human insulin mixes (Actraphane, 
Humulin 30/70 and Insuman) with Biosulin 30/70, Biosulin 30/70 
achieved at least equivalent glycaemic control with no reported new 
or severe adverse events. This surveillance study of Biosulin 30/70 in 
a real-world medical practice setting expands the safety and efficacy 
data on record.
Despite the more complex production process and regulatory 
requirements for biosimilars, they offer a price reduction of between 
35% and 50% of the parent insulin and analogue insulins.[5]
 A meta-analysis to assess the effects of short-acting analogues in 
patients with type 2 diabetes failed to find any difference in HbA1c 
between regular human insulin and short-acting analogues.[5] There 
was, however, a small benefit in favour of short-acting analogue 
insulins in reducing the frequency of severe hypoglycaemic episodes 
from a median of 1.4 episodes per 100 patient years to 0.3 episodes. [5] 
Horvath et al.[6] compared long-acting analogues Detemir and Lantus 
with NPH insulin in adult patients with type 2 diabetes and also 
found no A1c advantage. The efficacy of these analogue insulins in 
type 1 diabetes is more established although the actual advantages 
are minimal.[7]
Overall, more expensive analogue insulins offer minimal 
advantages over regular insulin in the management of type 2 
diabetes, and increased use of biosimilar insulins has the potential for 
significant cost savings with no loss in patients’ glycaemic outcomes. 
There is no doubt that biosimilar insulins such as Biosulin will play 
an ever-increasing role in the management of diabetes.
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